Revenue - Summary of Disaggregation of Revenue Within Reportable Segment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Total revenue	$ 132,584	$ 99,951	$ 105,136
Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	60,614	54,621	46,478
Royalties & License Fees - Performance Coatings [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	62,398	36,248	47,056
Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	9,572	9,082	11,602
Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	132,584	99,951	105,136
Operating Segments [Member] | Medical Device [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	105,783	72,389	78,253
Operating Segments [Member] | Medical Device [Member] | Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	34,126	27,930	21,777
Operating Segments [Member] | Medical Device [Member] | Royalties & License Fees - Performance Coatings [Member] | Performance Coatings [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	32,812	30,547	31,007
Operating Segments [Member] | Medical Device [Member] | License Fees - SurVeil DCB [Member] | SurVeil DCB - Abbott Agreement [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	29,586	5,701	16,049
Operating Segments [Member] | Medical Device [Member] | Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	9,259	8,211	9,420
Operating Segments [Member] | In Vitro Diagnostics [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	26,801	27,562	26,883
Operating Segments [Member] | In Vitro Diagnostics [Member] | Product Sales [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	26,488	26,691	24,701
Operating Segments [Member] | In Vitro Diagnostics [Member] | Research, Development and Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 313	$ 871	$ 2,182